The Canaries in the Human DNA Mine
DOI:
https://doi.org/10.56098/ijvtpr.v3i1.83Keywords:
genetically modified organisms, GMO, Moderna, modified RNA, modRNA, Pfizer, retroposition, reverse transcription, SARS-CoV-2Abstract
Decades of sophisticated and detailed legislation created to safeguard humanity from exposure to genetically modified organisms was ignored or legislated away in an instant when SARS-CoV-2 arrived. It seems this banishment was done with intention and not for the good of humanity. The lipid nanoparticles containing modified RNAs, the so-called “vaccines”, from the beginning fulfilled the legal definitions for being categorized as genetically modified organisms. Pfizer, Moderna, and regulators all knew this. The claims by Pfizer and Moderna repeated by regulators and complicit politicians that modified RNAs do not enter the cell nucleus and reverse transcribe into the human genome were lies constructed knowingly. Over four decades of scientific knowledge marked with Nobel Prizes pointed to modified RNAs integrating into the human genome. The knowledge of retroposition preceded the use of modified RNAs in response to the pandemic, but the WHO and regulatory experts did not inform the global population about these facts. This article retraces the steps in what appears to be a sophisticated deception played out in legal language, technical scientific jargon, and by medical regulatory bodies acting as if they were serving public health.
References
Aldén, M., Olofsson Falla, F., Yang, D., Barghouth, M., Luan, C., Rasmussen, M., De Marinis, Y (2022). Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line. Curr. Issues Mol. Biol. 2022, 44, 1115-1126. https://doi.org/10.3390/cimb44030073
Casola C., Betrán E (2017). The Genomic Impact of Gene Retrocopies: What Have We Learned from Comparative Genomics, Population Genomics, and Transcriptomic Analyses?, Genome Biology and Evolution, Volume 9, Issue 6, June 2017, Pages 1351–1373, https://doi.org/10.1093/gbe/evx081
Cheetham S.W., Faulkner G.J., Dinger, M.E (2020). Overcoming challenges and dogmas to understand the functions of pseudogenes. Nat Rev Genet 21, 191–201 (2020). https://doi.org/10.1038/s41576-019-0196-1
Domazet-Lošo, T (2022). mRNA Vaccines: Why Is the Biology of Retroposition Ignored? Genes 2022, 13, 719. https://doi.org/10.3390/genes13050719 Video: mRNA vaccines: Why is the biology of retroposition ignored? by T. Domazet-Lošo https://www.youtube.com/watch?v=EtKyuanx37Q
Video @ 27:48 mins/sec: https://www.youtube.com/watch?v=EtKyuanx37Q&t=1668s
Dulbecco, Renato. (1975). The Nobel Prize in Physiology or Medicine. NobelPrize.Org. Retrieved July 18, 2023, from https://www.nobelprize.org/prizes/medicine/1975/summary/
EMA: Pfizer EPAR (2021), Committee for Medicinal Products for Human Use (CHMP), 19 February 2021, Assessment report, Comirnaty, Common name: COVID-19 mRNA vaccine (nucleoside-modified) https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf
Moderna EPAR (2021), Committee for Medicinal Products for Human Use (CHMP), 11 March 2021, Assessment report COVID-19 Vaccine Moderna, Common name: COVID-19 mRNA Vaccine (nucleoside-modified) https://www.ema.europa.eu/en/documents/assessment-report/spikevax-previously-covid-19-vaccine-moderna-epar-public-assessment-report_en.pdf
EU: Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32001L0018
Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use https://www.legislation.gov.uk/eudr/2001/83/contents
Article 8(3): https://www.legislation.gov.uk/eudr/2001/83/article/8
Annex 1: https://www.legislation.gov.uk/eudr/2001/83/annex/I
Directive 2009/41/EC of the European Parliament and of the Council of 6 May 2009 on the contained use of genetically modified micro-organisms. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32009L0041
Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32004R0726
Regulation (EU) 2020/1043 of the European Parliament and of the Council of 15 July 2020 on the conduct of clinical trials with and supply of medicinal products for human use containing or consisting of genetically modified organisms intended to treat or prevent coronavirus disease (COVID-19). https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32020R1043
Gene Technology Act 2000. http://classic.austlii.edu.au/au/legis/cth/consol_act/gta2000162/ Section 10: http://classic.austlii.edu.au/au/legis/cth/consol_act/gta2000162/s10.html
Kaessmann H., Vinckenbosch N (2009). Long M. RNA-based gene duplication: mechanistic and evolutionary insights. Nat Rev Genet 10, 19–31 (2009). https://doi.org/10.1038/nrg2487
McKernan, 26 February 2023. Deep sequencing of the Moderna and Pfizer bivalent vaccines identifies contamination of expression vectors designed for plasmid amplification in bacteria (aka Curious Kittens). https://anandamide.substack.com/p/curious-kittens
McKernan, K., Helbert, Y., Kane, L., McLaughlin, S (2023). Sequencing of bivalent Moderna and Pfizer mRNA vaccines reveals nanogram to microgram quantities of expression vector dsDNA per dose. OSFPREPRINTS, preprint. https://osf.io/b9t7m/
Nance K., Meier J., (2021). Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines. ACS Cent. Sci. 2021, 7, 5, 748–756 Publication Date: April 6, 2021 https://doi.org/10.1021/acscentsci.1c00197
Nobel Prize, Barbara McClintock, Nobel Prize in Physiology or Medicine 1983.
https://www.nobelprize.org/womenwhochangedscience/stories/barbara-mcclintock
Office of the Gene Technology Regulator (OGTR) (Australia)
OGTR, AstraZeneca GMO license, 8 February 2021. DIR 180 Commercial supply of a genetically modified COVID-19 vaccine. https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-180
Qin Z, Bouteau A, Herbst C, Igyártó BZ (2022). Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion. PLoS Pathog 18(9): e1010830. https://doi.org/10.1371/journal.ppat.1010830
Sattar S., Kabat J., Jerome K., Feldmann F., Bailey K., Mehedi M, (2022). Nuclear translocation of spike mRNA and protein is a novel pathogenic feature of SARS-CoV-2. Preprint. https://doi.org/10.1101/2022.09.27.509633
UNESCO, Universal Declaration on Bioethics and Human Rights, Date of Adoption 19 October 2005. https://www.unesco.org/en/legal-affairs/universal-declaration-bioethics-and-human-rights
UN, International Covenant on Civil and Political Rights, Date of Adoption 16 December 1966. https://www.ohchr.org/en/instruments-mechanisms/instruments/international-covenant-civil-and-political-rights
WHO, 22 December 2020. Evaluation of the quality, safety and efficacy of RNA-based prophylactic vaccines for infectious diseases: regulatory considerations. https://www.who.int/docs/default-source/biologicals/ecbs/reg-considerations-on-rna-vaccines_1st-draft_pc_tz_22122020.pdf
Zhang W., Xie C., Ullrich K., Tautz D (2021). The mutational load in natural populations is significantly affected by high primary rates of retroposition. PNAS Vol. 118, No. 6, February 9, 2021. https://doi.org/10.1073/pnas.2013043118
Knezevic, I.; Liu, M.A.; Peden, K.; Zhou, T.; Kang, H.-N. Development of MRNA Vaccines: Scientific and Regulatory Issues. Vaccines 2021, 9, 81. [Google Scholar] [CrossRef]
Park, J.W.; Lagniton, P.N.P.; Liu, Y.; Xu, R.-H. MRNA Vaccines for COVID-19: What, Why and How. Int. J. Biol. Sci. 2021, 17, 1446–1460. [Google Scholar] [CrossRef]
Pardi, N.; Hogan, M.J.; Porter, F.W.; Weissman, D. MRNA Vaccines—A New Era in Vaccinology. Nat. Rev. Drug Discov. 2018, 17, 261–279. [Google Scholar] [CrossRef][Green Version]
Geall, A.J.; Mandl, C.W.; Ulmer, J.B. RNA: The New Revolution in Nucleic Acid Vaccines. Semin. Immunol. 2013, 25, 152–159. [Google Scholar] [CrossRef]
Sahin, U.; Karikó, K.; Türeci, Ö. MRNA-Based Therapeutics—Developing a New Class of Drugs. Nat. Rev. Drug Discov. 2014, 13, 759–780. [Google Scholar] [CrossRef]
Kreiter, S.; Diken, M.; Selmi, A.; Türeci, Ö.; Sahin, U. Tumor Vaccination Using Messenger RNA: Prospects of a Future Therapy. Curr. Opin. Immunol. 2011, 23, 399–406. [Google Scholar] [CrossRef]
Weissman, D. MRNA Transcript Therapy. Expert Rev. Vaccines 2015, 14, 265–281. [Google Scholar] [CrossRef]
Maruggi, G.; Zhang, C.; Li, J.; Ulmer, J.B.; Yu, D. MRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol. Ther. 2019, 27, 757–772. [Google Scholar] [CrossRef][Green Version]
Dammes, N.; Peer, D. Paving the Road for RNA Therapeutics. Trends Pharmacol. Sci. 2020, 41, 755–775. [Google Scholar] [CrossRef]
Fuller, D.H.; Berglund, P. Amplifying RNA Vaccine Development. N. Engl. J. Med. 2020, 382, 2469–2471. [Google Scholar] [CrossRef]
Tombácz, I.; Weissman, D.; Pardi, N. Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination. In DNA Vaccines; Sousa, Â., Ed.; Methods in Molecular Biology; Springer: New York, NY, USA, 2021; Volume 2197, pp. 13–31. ISBN 978-1-07-160871-5. [Google Scholar]
Gerer, K.F.; Hoyer, S.; Dörrie, J.; Schaft, N. Electroporation of MRNA as Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins. In RNA Vaccines; Kramps, T., Elbers, K., Eds.; Methods in Molecular Biology; Springer: New York, NY, USA, 2017; Volume 1499, pp. 165–178. ISBN 978-1-4939-6479-6. [Google Scholar]
Pardi, N.; Weissman, D. Nucleoside Modified MRNA Vaccines for Infectious Diseases. In RNA Vaccines; Kramps, T., Elbers, K., Eds.; Methods in Molecular Biology; Springer: New York, NY, USA, 2017; Volume 1499, pp. 109–121. ISBN 978-1-4939-6479-6. [Google Scholar]
Hinz, T.; Kallen, K.; Britten, C.M.; Flamion, B.; Granzer, U.; Hoos, A.; Huber, C.; Khleif, S.; Kreiter, S.; Rammensee, H.-G.; et al. The European Regulatory Environment of RNA-Based Vaccines. In RNA Vaccines; Kramps, T., Elbers, K., Eds.; Methods in Molecular Biology; Springer: New York, NY, USA, 2017; Volume 1499, pp. 203–222. ISBN 978-1-4939-6479-6. [Google Scholar]
Naik, R.; Peden, K. Regulatory Considerations on the Development of MRNA Vaccines. In Current Topics in Microbiology and Immunology; Springer: Berlin/Heidelberg, Germany, 2020. [Google Scholar]
World Health Organization. Evaluation of the Quality, Safety and Efficacy of RNA-Based Prophylactic Vaccines for Infectious Diseases: Regulatory Considerations. (Draft). 2020. Available online: https://www.who.int/docs/default-source/biologicals/ecbs/reg-considerations-on-rna-vaccines_1st-draft_pc_tz_22122020.pdf (accessed on 11 January 2021).
World Health Organization. Background Document on the mRNA Vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19. 2021. Available online: https://www.who.int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19 (accessed on 12 February 2021).
World Health Organization. Background Document on the mRNA-1273 Vaccine (Moderna) against COVID-19. 2021. Available online: https://www.who.int/publications/i/item/background-document-on-the-mrna-1273-vaccine-(moderna)-against-covid-19 (accessed on 12 February 2021).
Funk, C.D.; Laferrière, C.; Ardakani, A. A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic. Front. Pharmacol. 2020, 11, 937. [Google Scholar] [CrossRef]
Zhang, C.; Maruggi, G.; Shan, H.; Li, J. Advances in MRNA Vaccines for Infectious Diseases. Front. Immunol. 2019, 10, 594. [Google Scholar] [CrossRef][Green Version]
Youn, H.; Chung, J.-K. Modified MRNA as an Alternative to Plasmid DNA (PDNA) for Transcript Replacement and Vaccination Therapy. Expert Opin. Biol. Ther. 2015, 15, 1337–1348. [Google Scholar] [CrossRef]
Yamamoto, A.; Kormann, M.; Rosenecker, J.; Rudolph, C. Current Prospects for MRNA Gene Delivery. Eur. J. Pharm. Biopharm. 2009, 71, 484–489. [Google Scholar] [CrossRef]
Ewing, A.D.; Ballinger, T.J.; Earl, D.; Broad Institute Genome Sequencing and Analysis Program and Platform; Harris, C.C.; Ding, L.; Wilson, R.K.; Haussler, D. Retrotransposition of Gene Transcripts Leads to Structural Variation in Mammalian Genomes. Genome Biol. 2013, 14, R22. [Google Scholar] [CrossRef] [PubMed][Green Version]
ICGC Breast Cancer Group; Cooke, S.L.; Shlien, A.; Marshall, J.; Pipinikas, C.P.; Martincorena, I.; Tubio, J.M.C.; Li, Y.; Menzies, A.; Mudie, L.; et al. Processed Pseudogenes Acquired Somatically during Cancer Development. Nat. Commun. 2014, 5, 3644. [Google Scholar] [CrossRef]
Scott, E.; Devine, S. The Role of Somatic L1 Retrotransposition in Human Cancers. Viruses 2017, 9, 131. [Google Scholar] [CrossRef]
Bim, L.V.; Navarro, F.C.P.; Valente, F.O.F.; Lima-Junior, J.V.; Delcelo, R.; Dias-da-Silva, M.R.; Maciel, R.M.B.; Galante, P.A.F.; Cerutti, J.M. Retroposed Copies of RET Gene: A Somatically Acquired Event in Medullary Thyroid Carcinoma. BMC Med. Genom. 2019, 12, 104. [Google Scholar] [CrossRef]
PCAWG Structural Variation Working Group; PCAWG Consortium; Rodriguez-Martin, B.; Alvarez, E.G.; Baez-Ortega, A.; Zamora, J.; Supek, F.; Demeulemeester, J.; Santamarina, M.; Ju, Y.S.; et al. Pan-Cancer Analysis of Whole Genomes Identifies Driver Rearrangements Promoted by LINE-1 Retrotransposition. Nat. Genet. 2020, 52, 306–319. [Google Scholar] [CrossRef][Green Version]
De Boer, M.; van Leeuwen, K.; Geissler, J.; Weemaes, C.M.; van den Berg, T.K.; Kuijpers, T.W.; Warris, A.; Roos, D. Primary Immunodeficiency Caused by an Exonized Retroposed Gene Copy Inserted in the CYBB Gene. Hum. Mutat. 2014, 35, 486–496. [Google Scholar] [CrossRef]
Kazazian, H.H. Processed Pseudogene Insertions in Somatic Cells. Mob. DNA 2014, 5, 20. [Google Scholar] [CrossRef][Green Version]
Kaessmann, H.; Vinckenbosch, N.; Long, M. RNA-Based Gene Duplication: Mechanistic and Evolutionary Insights. Nat. Rev. Genet. 2009, 10, 19–31. [Google Scholar] [CrossRef][Green Version]
Casola, C.; Betrán, E. The Genomic Impact of Gene Retrocopies: What Have We Learned from Comparative Genomics, Population Genomics, and Transcriptomic Analyses? Genome Biol. Evol. 2017, 9, 1351–1373. [Google Scholar] [CrossRef]
Zhang, W.; Xie, C.; Ullrich, K.; Zhang, Y.E.; Tautz, D. The Mutational Load in Natural Populations Is Significantly Affected by High Primary Rates of Retroposition. Proc. Natl. Acad. Sci. USA 2021, 118, e2013043118. [Google Scholar] [CrossRef]
Esnault, C.; Maestre, J.; Heidmann, T. Human LINE Retrotransposons Generate Processed Pseudogenes. Nat. Genet. 2000, 24, 363–367. [Google Scholar] [CrossRef]
Tan, S.; Cardoso-Moreira, M.; Shi, W.; Zhang, D.; Huang, J.; Mao, Y.; Jia, H.; Zhang, Y.; Chen, C.; Shao, Y.; et al. LTR-Mediated Retroposition as a Mechanism of RNA-Based Duplication in Metazoans. Genome Res. 2016, 26, 1663–1675. [Google Scholar] [CrossRef] [PubMed][Green Version]
Levin, H.L.; Moran, J.V. Dynamic Interactions between Transposable Elements and Their Hosts. Nat. Rev. Genet. 2011, 12, 615–627. [Google Scholar] [CrossRef]
Newkirk, S.J.; Lee, S.; Grandi, F.C.; Gaysinskaya, V.; Rosser, J.M.; Vanden Berg, N.; Hogarth, C.A.; Marchetto, M.C.N.; Muotri, A.R.; Griswold, M.D.; et al. Intact PiRNA Pathway Prevents L1 Mobilization in Male Meiosis. Proc. Natl. Acad. Sci. USA 2017, 114, E5635–E5644. [Google Scholar] [CrossRef] [PubMed][Green Version]
Ostertag, E.M.; DeBerardinis, R.J.; Goodier, J.L.; Zhang, Y.; Yang, N.; Gerton, G.L.; Kazazian, H.H. A Mouse Model of Human L1 Retrotransposition. Nat. Genet. 2002, 32, 655–660. [Google Scholar] [CrossRef]
Belancio, V.P.; Roy-Engel, A.M.; Pochampally, R.R.; Deininger, P. Somatic Expression of LINE-1 Elements in Human Tissues. Nucleic Acids Res. 2010, 38, 3909–3922. [Google Scholar] [CrossRef][Green Version]
Ergün, S.; Buschmann, C.; Heukeshoven, J.; Dammann, K.; Schnieders, F.; Lauke, H.; Chalajour, F.; Kilic, N.; Strätling, W.H.; Schumann, G.G. Cell Type-Specific Expression of LINE-1 Open Reading Frames 1 and 2 in Fetal and Adult Human Tissues. J. Biol. Chem. 2004, 279, 27753–27763. [Google Scholar] [CrossRef][Green Version]
Lazaros, L.; Kitsou, C.; Kostoulas, C.; Bellou, S.; Hatzi, E.; Ladias, P.; Stefos, T.; Markoula, S.; Galani, V.; Vartholomatos, G.; et al. Retrotransposon Expression and Incorporation of Cloned Human and Mouse Retroelements in Human Spermatozoa. Fertil. Steril. 2017, 107, 821–830. [Google Scholar] [CrossRef][Green Version]
Giordano, R.; Magnano, A.R.; Zaccagnini, G.; Pittoggi, C.; Moscufo, N.; Lorenzini, R.; Spadafora, C. Reverse Transcriptase Activity in Mature Spermatozoa of Mouse. J. Cell Biol. 2000, 148, 1107–1114. [Google Scholar] [CrossRef]
Georgiou, I.; Noutsopoulos, D.; Dimitriadou, E.; Markopoulos, G.; Apergi, A.; Lazaros, L.; Vaxevanoglou, T.; Pantos, K.; Syrrou, M.; Tzavaras, T. Retrotransposon RNA Expression and Evidence for Retrotransposition Events in Human Oocytes. Hum. Mol. Genet. 2009, 18, 1221–1228. [Google Scholar] [CrossRef][Green Version]
Richardson, S.R.; Faulkner, G.J. Heritable L1 Retrotransposition Events during Development: Understanding Their Origins: Examination of Heritable, Endogenous L1 Retrotransposition in Mice Opens up Exciting New Questions and Research Directions. BioEssays 2018, 40, 1700189. [Google Scholar] [CrossRef][Green Version]
Kano, H.; Godoy, I.; Courtney, C.; Vetter, M.R.; Gerton, G.L.; Ostertag, E.M.; Kazazian, H.H. L1 Retrotransposition Occurs Mainly in Embryogenesis and Creates Somatic Mosaicism. Genes Dev. 2009, 23, 1303–1312. [Google Scholar] [CrossRef][Green Version]
Kohlrausch, F.B.; Berteli, T.S.; Wang, F.; Navarro, P.A.; Keefe, D.L. Control of LINE-1 Expression Maintains Genome Integrity in Germline and Early Embryo Development. Reprod. Sci. 2021. [Google Scholar] [CrossRef]
Richardson, S.R.; Gerdes, P.; Gerhardt, D.J.; Sanchez-Luque, F.J.; Bodea, G.-O.; Muñoz-Lopez, M.; Jesuadian, J.S.; Kempen, M.-J.H.C.; Carreira, P.E.; Jeddeloh, J.A.; et al. Heritable L1 Retrotransposition in the Mouse Primordial Germline and Early Embryo. Genome Res. 2017, 27, 1395–1405. [Google Scholar] [CrossRef][Green Version]
Goodier, J.L. Restricting Retrotransposons: A Review. Mob. DNA 2016, 7, 16. [Google Scholar] [CrossRef][Green Version]
Del Re, B.; Giorgi, G. Long INterspersed Element-1 Mobility as a Sensor of Environmental Stresses. Environ. Mol. Mutagen. 2020, 61, 465–493. [Google Scholar] [CrossRef]
Rangwala, S.H.; Zhang, L.; Kazazian, H.H. Many LINE1 Elements Contribute to the Transcriptome of Human Somatic Cells. Genome Biol. 2009, 10, R100. [Google Scholar] [CrossRef][Green Version]
Schwertz, H.; Rowley, J.W.; Schumann, G.G.; Thorack, U.; Campbell, R.A.; Manne, B.K.; Zimmerman, G.A.; Weyrich, A.S.; Rondina, M.T. Endogenous LINE-1 (Long Interspersed Nuclear Element-1) Reverse Transcriptase Activity in Platelets Controls Translational Events Through RNA–DNA Hybrids. ATVB 2018, 38, 801–815. [Google Scholar] [CrossRef]
Banaz-Yaşar, F.; Steffen, G.; Hauschild, J.; Bongartz, B.M.; Schumann, G.G.; Ergün, S. LINE-1 Retrotransposition Events Affect Endothelial Proliferation and Migration. Histochem. Cell Biol. 2010, 134, 581–589. [Google Scholar] [CrossRef]
Kazazian, H.H.; Moran, J.V. Mobile DNA in Health and Disease. N. Engl. J. Med. 2017, 377, 361–370. [Google Scholar] [CrossRef]
Upton, K.R.; Gerhardt, D.J.; Jesuadian, J.S.; Richardson, S.R.; Sánchez-Luque, F.J.; Bodea, G.O.; Ewing, A.D.; Salvador-Palomeque, C.; van der Knaap, M.S.; Brennan, P.M.; et al. Ubiquitous L1 Mosaicism in Hippocampal Neurons. Cell 2015, 161, 228–239. [Google Scholar] [CrossRef][Green Version]
Terry, D.M.; Devine, S.E. Aberrantly High Levels of Somatic LINE-1 Expression and Retrotransposition in Human Neurological Disorders. Front. Genet. 2020, 10, 1244. [Google Scholar] [CrossRef][Green Version]
Muotri, A.R.; Chu, V.T.; Marchetto, M.C.N.; Deng, W.; Moran, J.V.; Gage, F.H. Somatic Mosaicism in Neuronal Precursor Cells Mediated by L1 Retrotransposition. Nature 2005, 435, 903–910. [Google Scholar] [CrossRef][Green Version]
Coufal, N.G.; Garcia-Perez, J.L.; Peng, G.E.; Yeo, G.W.; Mu, Y.; Lovci, M.T.; Morell, M.; O’Shea, K.S.; Moran, J.V.; Gage, F.H. L1 Retrotransposition in Human Neural Progenitor Cells. Nature 2009, 460, 1127–1131. [Google Scholar] [CrossRef][Green Version]
Baillie, J.K.; Barnett, M.W.; Upton, K.R.; Gerhardt, D.J.; Richmond, T.A.; De Sapio, F.; Brennan, P.M.; Rizzu, P.; Smith, S.; Fell, M.; et al. Somatic Retrotransposition Alters the Genetic Landscape of the Human Brain. Nature 2011, 479, 534–537. [Google Scholar] [CrossRef][Green Version]
Macia, A.; Widmann, T.J.; Heras, S.R.; Ayllon, V.; Sanchez, L.; Benkaddour-Boumzaouad, M.; Muñoz-Lopez, M.; Rubio, A.; Amador-Cubero, S.; Blanco-Jimenez, E.; et al. Engineered LINE-1 Retrotransposition in Nondividing Human Neurons. Genome Res. 2017, 27, 335–348. [Google Scholar] [CrossRef][Green Version]
Sender, R.; Fuchs, S.; Milo, R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016, 14, e1002533. [Google Scholar] [CrossRef] [PubMed][Green Version]
Marinov, G.K.; Williams, B.A.; McCue, K.; Schroth, G.P.; Gertz, J.; Myers, R.M.; Wold, B.J. From Single-Cell to Cell-Pool Transcriptomes: Stochasticity in Gene Expression and RNA Splicing. Genome Res. 2014, 24, 496–510. [Google Scholar] [CrossRef][Green Version]
Orlandini von Niessen, A.G.; Poleganov, M.A.; Rechner, C.; Plaschke, A.; Kranz, L.M.; Fesser, S.; Diken, M.; Löwer, M.; Vallazza, B.; Beissert, T.; et al. Improving MRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening. Mol. Ther. 2019, 27, 824–836. [Google Scholar] [CrossRef][Green Version]
Verbeke, R.; Lentacker, I.; De Smedt, S.C.; Dewitte, H. The Dawn of MRNA Vaccines: The COVID-19 Case. J. Control. Release 2021, 333, 511–520. [Google Scholar] [CrossRef]
Shi, K.; Liu, T.; Fu, H.; Li, W.; Zheng, X. Genome-Wide Analysis of LncRNA Stability in Human. PLoS Comput. Biol. 2021, 17, e1008918. [Google Scholar] [CrossRef]
Mauger, D.M.; Cabral, B.J.; Presnyak, V.; Su, S.V.; Reid, D.W.; Goodman, B.; Link, K.; Khatwani, N.; Reynders, J.; Moore, M.J.; et al. MRNA Structure Regulates Protein Expression through Changes in Functional Half-Life. Proc. Natl. Acad. Sci. USA 2019, 116, 24075–24083. [Google Scholar] [CrossRef][Green Version]
Zhang, Y.; Li, S.; Abyzov, A.; Gerstein, M.B. Landscape and Variation of Novel Retroduplications in 26 Human Populations. PLoS Comput. Biol. 2017, 13, e1005567. [Google Scholar] [CrossRef]
Verbeke, R.; Lentacker, I.; De Smedt, S.C.; Dewitte, H. Three Decades of Messenger RNA Vaccine Development. Nano Today 2019, 28, 100766. [Google Scholar] [CrossRef]
Liu, A. Comparison of Plasmid DNA and MRNA as Vaccine Technologies. Vaccines 2019, 7, 37. [Google Scholar] [CrossRef][Green Version]
Adams, J.W.; Kaufman, R.E.; Kretschmer, P.J.; Harrison, M.; Nienhuis, A.W. A Family of Long Reiterated DNA Sequences, One Copy of Which Is next to the Human Beta Globin Gene. Nucl. Acids Res. 1980, 8, 6113–6128. [Google Scholar] [CrossRef] [PubMed][Green Version]
Skowronski, J.; Singer, M.F. Expression of a Cytoplasmic LINE-1 Transcript Is Regulated in a Human Teratocarcinoma Cell Line. Proc. Natl. Acad. Sci. USA 1985, 82, 6050–6054. [Google Scholar] [CrossRef] [PubMed][Green Version]
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Julian Gillespie
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The copyright for materials in this journal, IJVTPR, is owned by the author. The author, however, grants first right of publication to the journal, IJVTPR and assures the editorial staff of the journal that the work submitted has not simultaneously been submitted to any other journal, nor is it under consideration for publication by any other journal. If any portion of the work submitted has appeared elsewhere, the quoted material is properly cited and credit is given to the original publisher. The submitting author (or the principal and corresponding author of the work) also assures the editors of IJVTPR that he or she has obtained all required written permissions from any quoted authors or publishers of quoted materials. The submitting author also agrees to hold IJVTPR and its editorial staff harmless from any infractions of copyright law that may be discovered at any time in the future in the submitted work. The author assures the editorial staff at IJVTPR that none of the work submitted is plagiarized, and that any recycled or precycled material by the author is identified as such with proper credits in the text to any other parties holding a copyright interest in the quoted material.